- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02323750
TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study (TransitionCHF)
November 21, 2023 updated by: Gerd Hasenfus, University of Göttingen
Systolic Dysfunction to Congestive Heart Failure Cohort Study
TransitionCHF aims to recruit a unique cohort of patients with asymptomatic left ventricular dysfunction (NYHA I) to study the progression to symptomatic (>NYHA I) HF and to identify parameters/ biomarkers promoting and predicting the individual risk of transition.
Results from TransitionCHF Cohort Study will inform and refine current treatment guidelines.
The implementation of common patient data sets and biobanking standards will enable data and biomaterial sharing with other study groups of the German Center for Cardiovascular Research (DZHK).
This study will set the standard for a unique DZHK heart failure database and Biobank for innovative preclinical and clinical trials.
Study Overview
Status
Active, not recruiting
Study Type
Observational
Enrollment (Actual)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Göttingen, Germany, 37075
- University Medical Center Goettingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The DZHK TransitionCHF Cohort Study will include patients with systolic dysfunction (NYHA I), i.e. (1) patients without a history of HF symptoms and (2) patients who reversed from symptomatic HF.
Patients will be recruited prospectively at the participating DZHK centres, non-DZHK university hospitals and centers.
Description
Inclusion Criteria:
- Asymptomatic systolic dysfunction (defined as: ejection fraction < 40% by echocardiography or MRI; documented within the last 3 months prior to baseline visit)
- A maximum of one hospitalization for heart failure (defined as hospitalization with signs and symptoms of heart failure requiring intravenous loop diuretic therapy within 48 hours after hospital admission) at least 2 years prior to the baseline visit
- No heart failure symptoms (NYHA II, III or IV) upon inclusion
- 6MWD ≥ 80% of reference values
- Written informed consent
- Age ≥ 18 years
Exclusion Criteria:
- Symptomatic heart failure (NYHA>I) at baseline visit
- Any significant valvular disease (> 2nd degree)
- Severe pulmonary disease (e.g. FEV1/FVC <0.7 and FEV1<50%)
- Severe renal disease (GFR < 15 ml/min)
- ejection fraction at baseline visit ≥ 50% by echocardiography or MRI
- Life expectancy < 1 year
- Pericardial disease
- Hypertrophic cardiomyopathy
- Myocardial infarction within the last 3 months
- Planned cardiac surgical intervention within 3 months after inclusion
- Geographical reasons (e. g. patients living outside Germany or planning to move abroad)
- Inability to give informed consent (e. g. mental disorders)
- Therapy with loop diuretics (e.g. torasemide, furosemide, piretanide) within 4 weeks prior to inclusion/baseline visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite endpoint of hospitalization for heart failure and cardiovascular death
Time Frame: 0.5 - 13 years
|
0.5 - 13 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2014
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
December 18, 2014
First Submitted That Met QC Criteria
December 18, 2014
First Posted (Estimated)
December 23, 2014
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TransitionCHF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systolic Dysfunction, Transition, Heart Failure, Biobank
-
Royal Cornwall Hospitals TrustSuspendedHeart Failure | Cognitive Impairment | Cognitive Change | Heart Failure, Systolic | Left Ventricular Dysfunction | Systolic Heart Failure | Cognitive Impairment, Mild | Left Ventricular Systolic Dysfunction | Systolic DysfunctionUnited Kingdom
-
Heinrich-Heine University, DuesseldorfRecruitingHeart Failure With Preserved Ejection Fraction | Diastolic Dysfunction | Systolic DysfunctionGermany
-
Merck Sharp & Dohme LLCRecruitingHeart Failure | Left Ventricular Systolic DysfunctionKorea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa
-
Flinders UniversitySouth Australian Health and Medical Research InstituteActive, not recruitingHeart Failure | Left Ventricular Systolic DysfunctionAustralia, Germany, United Kingdom
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Center for Research...CompletedHeart Failure | Asymptomatic Systolic DysfunctionUnited States
-
CytokineticsCompletedChronic Heart Failure | Pharmacokinetics | Left Ventricular Systolic Dysfunction | Left Ventricular Ejection Fraction | Modified Release Oral Formulation | History of Chronic Heart Failure | EchocardiogramUnited States, Canada, Italy, Netherlands, United Kingdom, Belgium, Czechia, Australia, Hungary, Poland, Bulgaria, Lithuania, Germany
-
Portsmouth Hospitals NHS TrustVifor PharmaRecruitingHeart Failure With Reduced Ejection Fraction | Left Ventricular Systolic Dysfunction | HyperkalaemiaUnited Kingdom
-
CardioKinetix, IncTerminatedCongestive Heart Failure | Left Ventricular (LV) Systolic DysfunctionUnited States, Canada
-
Mayo ClinicCompletedHeart Failure | Asymptomatic Left Ventricular Systolic Dysfunction (Disorder)United States
-
CytokineticsCompletedHeart FailureUnited States, Canada, Germany, Italy, Netherlands, Belgium, France, Czechia, Australia, Russian Federation, Hungary, Poland, Bulgaria, Slovakia, United Kingdom, Finland, Greece, Lithuania, Norway